2. Disease Areas
  3. Urogenital Disease
  4. Renal Disease
  5. Polycystic Kidney Disease

Polycystic Kidney Disease

Polycystic kidney disease (PKD) is a genetic disorder characterized by the growth of numerous fluid-filled cysts in the kidneys, leading to impaired kidney function and potential progression to end-stage renal disease (ESRD). The two main forms are autosomal dominant PKD (ADPKD), which is the most common type and typically manifests in adulthood, and autosomal recessive PKD (ARPKD), a rarer and more severe form presenting in infancy or early childhood. ADPKD is further classified into types 1 and 2 based on the underlying genetic mutations. PKD causes a range of complications including hypertension, proteinuria, hematuria, flank pain, kidney stones, liver cysts, cardiovascular abnormalities, and an increased risk of intracranial aneurysms. While there is no cure, management focuses on controlling blood pressure, reducing symptoms, slowing disease progression, and monitoring for complications.

Polycystic Kidney Disease (7):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-10325
    CL-387785 194423-06-8 99.31%
    CL-387785 (EKI-785; WAY-EKI 785) is an orally active EGFR inhibitor with an IC50 of 370 pM. CL-387785 inhibits EGF-stimulated EGFR autophosphorylation with an IC50 of approximately 5 nM. CL-387,785 exerts selective inhibition on cell lines overexpressing EGFR or c-erbB-2, whereas it shows weak inhibitory effects on cell lines with low expression of these two receptors. CL-387785 effectively induces cell cycle arrest and apoptosis. CL-387785 can be used for the research of non-small cell lung cancer and autosomal recessive polycystic kidney disease.
    CL-387785
  • HY-146272
    Vasopressin V2 receptor antagonist 1 2648650-50-2
    Vasopressin V2 receptor antagonist 1 is a vasopressin V2 receptor (V2R) antagonist with a Ki value of 3.8 nM. Vasopressin V2 receptor antagonist 1 inhibits renal cyst formation in embryonic renal cyst models and mouse models. Vasopressin V2 receptor antagonist 1 can be used in research related to autosomal dominant polycystic kidney disease.
    Vasopressin V2 receptor antagonist 1
  • HY-105931
    Lixazinone 94192-59-3
    Lixazinone (RS-82856) is a selective inhibitor of cGMP-inhibited phosphodiesterase (PDE3) with an IC50 value of 22 nM. Lixazinone exhibits positive inotropic effects, afterload reduction and antithrombotic properties. Lixazinone increases cyclic adenosine monophosphate (cAMP) levels in human platelets, inhibits thrombin-induced aggregation of human platelets, and blocks the photolabeling of PDE3 active sites by [32P]cGMP. Lixazinone can be used in the research of polycystic kidney disease and congestive heart failure.
    Lixazinone
  • HY-113822
    Lixazinone hydrogensulfate 101626-67-9
    Lixazinone (RS-82856) hydrogensulfate is a selective inhibitor of cGMP-inhibited phosphodiesterase (PDE3) with an IC50 value of 22 nM. Lixazinone hydrogensulfate exhibits positive inotropic effects, afterload reduction and antithrombotic properties. Lixazinone hydrogensulfate increases cyclic adenosine monophosphate (cAMP) levels in human platelets, inhibits thrombin-induced aggregation of human platelets, and blocks the photolabeling of PDE3 active sites by [32P]cGMP. Lixazinone hydrogensulfate can be used in the research of polycystic kidney disease and congestive heart failure.
    Lixazinone hydrogensulfate
  • HY-180142
    XYDC2050
    XYDC2050 (Compound 29) is a selective vasopressin V2 receptor (V2R) antagonist with an IC50 of 27 nM and a Ki of 2.8 nM. XYDC2050 shows a Ki of 420.7 nM (SI = 162 fold) for V1R. XYDC2050 can inhibit Vasopressin (HY-B1811)-induced intracellular cyclic adenosine monophosphate (cAMP) accumulation with an IC50 of 12 nM. XYDC2050 can inhibit the growth of renal cysts, reduce the ratio of kidney weight to body weight and decrease the area of cysts and the cystic index. XYDC2050 can be used for the research of autosomal dominant polycystic kidney disease (ADPKD).
    XYDC2050
  • HY-177493A
    SSTR3 agonist-1 TFA
    SSTR3 agonist-1 TFA is a potent, orally active, and selective SSTR3 agnoist (EC50 =0.14 nM). SSTR3 agonist-1 TFA binds to SSTR3 receptor to inhibit cAMP activity. SSTR3 agonist-1 TFA decreases kidney weight and kidney cystic index (KCI) in a mouse model of autosomal dominant polycystic kidney disease (ADPKD). SSTR3 agonist-1 TFA can be used for ADPKD research.
    SSTR3 agonist-1 TFA
  • HY-10325R
    CL-387785 (Standard) 194423-06-8
    CL-387785 (EKI-785; WAY-EKI 785) (Standard) is the analytical standard of CL-387785 (HY-10325). This product is intended for research and analytical applications. CL-387785 is an orally active EGFR inhibitor with an IC50 of 370 pM. CL-387785 inhibits EGF-stimulated EGFR autophosphorylation with an IC50 of approximately 5 nM. CL-387,785 exerts selective inhibition on cell lines overexpressing EGFR or c-erbB-2, whereas it shows weak inhibitory effects on cell lines with low expression of these two receptors. CL-387785 effectively induces cell cycle arrest and apoptosis. CL-387785 can be used for the research of non-small cell lung cancer and autosomal recessive polycystic kidney disease.
    CL-387785 (Standard)